最新消息

PHILIPPINES: PILOT IMPLEMENTATION OF THE FDA CUSTOMER RELATION MANAGEMENT INFORMATION SYSTEM (CRMIS) — SEPTEMBER/OCTOBER 2023

PHILIPPINES: PILOT IMPLEMENTATION OF THE FDA CUSTOMER RELATION MANAGEMENT INFORMATION SYSTEM (CRMIS) — SEPTEMBER/OCTOBER 2023

  • 2023-09-27 05:49:24

The FDA has introduced the Customer Relation Management Information System (CRMIS), a digital platform that enables stakeholders and the public to submit inquiries and follow-ups. The system began on August 28, 2023, and will run until November 30, 2023, as part of the FDA's commitment to improving public health services and IT infrastructure.

了解更多
USA: US FDA's eSTAR Program – March/April, 2023

USA: US FDA's eSTAR Program – March/April, 2023

  • 2023-03-27 08:22:41

The US FDA starts to launch the so-called "eSTAR" Pilot with Health Canada. The eSTAR is an interactive medical device submission process and is expected to likely become the main path regarding medical device submissions for 510(k) and De novo registrations in the near future.

了解更多
USA: US FDA Voluntary Medical Device Manufacturing and Product Quality Pilot Program – June 2022

USA: US FDA Voluntary Medical Device Manufacturing and Product Quality Pilot Program – June 2022

  • 2022-06-29 03:18:32

The U.S. Food and Drug Administration has released a new draft guidance to further a voluntary program aiming to improve quality-related processes in medical device manufacturing. The concept comes from the Medical Device Innovation Consortium (MDIC), which assesses the capability and performance of key business processes using a maturity appraisal model tailored to the medical device industry. The overall stated goal is to enhance the quality processes and to improve the overall medical device quality, as to ultimately ensure better patient treatment outcomes.

了解更多
USA: Low-Risk Novel Products Can Avoid Automatic Class III Designation from US FDA – March, 2022

USA: Low-Risk Novel Products Can Avoid Automatic Class III Designation from US FDA – March, 2022

  • 2022-03-25 11:58:47

The US Food and Drug Administration (FDA) has updated several regulations affecting De Novo classification of novel medical devices. The main purpose is to present an objective and balance for the scientific evidence to be the foundation to grant a De Novo request. Also, the De Novo products will serve as future predicate devices for prospective 510(k) registration applications to improve and extend the existing 510(k) database.

了解更多
USA: FDA Transition Plan for Emergency Use Authorizations (EUAs) Medical Devices – February, 2022

USA: FDA Transition Plan for Emergency Use Authorizations (EUAs) Medical Devices – February, 2022

  • 2022-02-18 09:37:25

The US FDA is planning to issue transition plans for medical devices with Emergency Use Authorizations (EUAs). The EUA measure had previously been implemented in order to increase related necessary medical product supply on the US market.
As the Coronavirus Disease 2019 (COVID-19) pandemic gradually slows down, FDA has published a draft guidance to provide its recommendations to manufacturers, and in order to outline a roadmap for EUA devices to be able to transition after the emergency use declarations are no longer in effect in the future.

了解更多